IP Library Granted Patent US 10,232,063
Granted Patent B2
US 10,232,063 · App. 14/793,603 · Granted Mar 19, 2019

Method for treating lung carcinoma

Inventors: Jens Ricke (Potsdam, DE); Holger Amthauer (Magdeburg, DE); Oliver Grober (Magdeburg, DE)
Assignee: Sirtex Medical Limited
A61K51/1251A61K45/06A61N5/1001A61N2005/1021
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,232,063
App. No.
14/793,603
Granted
Mar 19, 2019
Kind
B2
Abstract

Accordingly, the present invention provides a method of treating lung neoplasia in a subject in need of treatment, by subjecting the patient to SIRT.

Claims (7)

1. A method for treating a lung neoplasia in a subject in need of treatment comprising subjecting the subject to selective internal radiation therapy with irradiated microparticles, wherein (i) the irradiated microparticles have a prescribed activity of 150 to 300 MBq and (ii) the therapy delivers a tumor dose of up to 6 MBq/ml of tumor volume to a site of treatment in the lung.

2. A method according to claim 1 wherein the site of treatment is restricted to the neoplasia.

3. A method according to claim 1 wherein the activity of the irradiated microparticles used in the selective internal radiation therapy is 180 to 250 MBq.

4. A method according to claim 1 wherein the activity of the irradiated microparticles used in the selective internal radiation therapy is approximately 200 MBq.

5. A method according to claim 1 wherein the therapy delivers a tumor dose of up to 5 MBq/ml of tumor volume to the site of treatment in the lung.

6. A method according to claim 1 wherein the therapy delivers a tumor dose of between 4 and 5 MBq/ml of tumor volume to the site of treatment in the lung.

7. A method according to claim 1 wherein the therapy is combined with a chemotherapeutic agent suitable for lung neoplastic treatment.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Jun 27, 2024
From: CHINA CITIC BANK INTERNATIONAL LIMITED
To: GRAND PHARMA SPHERE (AUSTRALIA BIDCO) PTY LTD; SIRTEX MEDICAL PTY LTD; SIRTEX MEDICAL PRODUCTS PTY LTD; SIRTEX GLOBAL PTY LTD; SIRTEX TECHNOLOGY PTY LTD
Reel/Frame 067944/0310 →
SECURITY INTEREST Recorded Jun 16, 2022
From: GRAND PHARMA SPHERE (AUSTRALIA BIDCO) PTY LTD; SIRTEX MEDICAL PTY LTD; SIRTEX MEDICAL PRODUCTS PTY LTD; SIRTEX GLOBAL PTY LTD; SIRTEX TECHNOLOGY PTY LTD
To: CHINA CITIC BANK INTERNATIONAL LIMITED
Reel/Frame 060450/0744 →
SECURITY INTEREST Recorded Nov 30, 2018
From: SIRTEX MEDICAL LIMITED
To: BANK OF CHINA LIMITED MACAU BRANCH
Reel/Frame 047691/0520 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 13, 2018
From: RICKE, JENS; AMTHAUER, HOLGER; GROBER, OLIVER
To: SIRTEX MEDICAL LIMITED
Reel/Frame 045575/0086 →
Continuity (2)
Provisional Application 62022645 · Jul 9, 2014
Related Publication 20160008497A1 · Jan 14, 2016